Hengehold Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.98M Sell
123,873
-89
-0.1% -$2.33K 0.23% 71
2026
Q1
$3.48M Sell
123,962
-5,256
-4% -$140K 0.3% 63
2025
Q4
$3.22M Sell
129,218
-4,604
-3% -$116K 0.27% 65
2025
Q3
$3.41M Buy
133,822
+2,598
+2% +$64.1K 0.29% 65
2025
Q2
$3.18M Buy
131,224
+3,486
+3% +$81.3K 0.29% 64
2025
Q1
$3.24M Buy
127,738
+7,892
+7% +$207K 0.31% 63
2024
Q4
$3.18M Buy
119,846
+2,043
+2% +$55.4K 0.3% 60
2024
Q3
$3.41M Buy
117,803
+7,303
+7% +$213K 0.32% 62
2024
Q2
$3.09M Sell
110,500
-5,788
-5% -$159K 0.32% 61
2024
Q1
$3.23M Buy
116,288
+22,535
+24% +$625K 0.34% 57
2023
Q4
$2.7M Sell
93,753
-1,828
-2% -$55.3K 0.32% 57
2023
Q3
$3.17M Buy
95,581
+2,310
+2% +$81.7K 0.41% 51
2023
Q2
$3.42M Sell
93,271
-686
-0.7% -$26.7K 0.45% 46
2023
Q1
$3.83M Sell
93,957
-261
-0.3% -$11.3K 0.53% 41
2022
Q4
$4.83M Buy
94,218
+2,076
+2% +$99.5K 0.67% 33
2022
Q3
$4.03M Buy
92,142
+350
+0.4% +$17K 0.62% 30
2022
Q2
$4.81M Buy
91,792
+875
+1% +$44.6K 0.68% 27
2022
Q1
$4.71M Sell
90,917
-297
-0.3% -$15.4K 0.64% 27
2021
Q4
$5.39M Sell
91,214
-651
-0.7% -$32.3K 0.66% 25
2021
Q3
$3.95M Sell
91,865
-1,736
-2% -$76.9K 0.52% 32
2021
Q2
$3.67M Buy
93,601
+786
+0.8% +$30.6K 0.48% 33
2021
Q1
$3.36M Buy
92,815
+7,375
+9% +$262K 0.47% 36
2020
Q4
$3.15M Sell
85,440
-3,150
-4% -$116K 0.47% 29
2020
Q3
$3.08M Buy
88,590
+145
+0.2% +$5.08K 0.5% 26
2020
Q2
$2.74M Sell
88,445
-3,690
-4% -$125K 0.49% 26
2020
Q1
$2.85M Sell
92,135
-2,581
-3% -$87.9K 0.61% 24
2019
Q4
$3.52M Buy
94,716
+2,732
+3% +$97.3K 0.6% 22
2019
Q3
$3.14M Buy
91,984
+158
+0.2% +$5.75K 0.58% 23
2019
Q2
$3.77M Buy
91,826
+5,087
+6% +$202K 0.72% 23
2019
Q1
$3.5M Buy
86,739
+1,991
+2% +$79.7K 0.82% 22
2018
Q4
$3.51M Sell
84,748
-328
-0.4% -$13.6K 1.13% 20
2018
Q3
$3.56M Sell
85,076
-3,591
-4% -$138K 0.89% 20
2018
Q2
$3.05M Buy
88,667
+11,684
+15% +$399K 0.79% 24
2018
Q1
$2.59M Buy
76,983
+1,196
+2% +$41.1K 0.68% 28
2017
Q4
$2.6M Buy
75,787
+238
+0.3% +$8.12K 0.68% 26
2017
Q3
$2.56M Buy
75,549
+672
+0.9% +$21.6K 0.68% 26
2017
Q2
$2.39M Buy
74,877
+1,881
+3% +$59.3K 0.67% 27
2017
Q1
$2.37M Buy
72,996
+4,740
+7% +$149K 0.66% 30
2016
Q4
$2.1M Buy
68,256
+3,552
+5% +$108K 0.64% 33
2016
Q3
$2.08M Buy
64,704
+955
+1% +$31.9K 0.66% 27
2016
Q2
$2.13M Buy
63,749
+651
+1% +$20.8K 0.69% 25
2016
Q1
$1.77M Buy
63,098
+49,684
+370% +$1.42M 0.57% 37
2015
Q4
$411K Buy
13,414
+632
+5% +$19.9K 0.15% 65
2015
Q3
$381K Buy
12,782
+1,116
+10% +$35.8K 0.17% 63
2015
Q2
$371K Sell
11,666
-623
-5% -$20.3K 0.13% 56
2015
Q1
$406K Hold
12,289
0.14% 55
2014
Q4
$363K Buy
12,289
+3,452
+39% +$99K 0.13% 56
2014
Q3
$248K Buy
8,837
+670
+8% +$18.8K 0.08% 62
2014
Q2
$230K Buy
8,167
+661
+9% +$18.8K 0.08% 64
2014
Q1
$229K Sell
7,506
-361
-5% -$10.8K 0.08% 65
2013
Q4
$229K Hold
7,867
0.08% 69
2013
Q3
$214K Sell
7,867
-103
-1% -$2.8K 0.09% 77
2013
Q2
$212K Buy
+7,970
New +$220K 0.09% 77

Other funds holding PFE

Hengehold Capital Management's PFE Position: Q2 2026 in Review

Hengehold Capital Management reduced its Pfizer (PFE) stake by 0.07% in Q2 2026, selling an estimated $2.33K and leaving 123,873 shares worth $2.98M. The position accounts for 0.23% of the portfolio, ranked #71.

Hengehold Capital Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.39M in Q4 2021. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Hengehold Capital Management held 123,873 shares of Pfizer worth $2.98M as of Q2 2026.
  • Hengehold Capital Management sold 89 Pfizer shares in Q2 2026, an estimated $2.33K.
  • Pfizer made up 0.23% of Hengehold Capital Management's portfolio in Q2 2026, its #71 holding.
  • Hengehold Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Hengehold Capital Management's Pfizer position peaked at $5.39M in Q4 2021.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Hengehold Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.